Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBS-002
- Development stage
- Preclinical
- Lead developer
- Juniper Biosciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JBS-002 is an investigational gallium-68 (Ga-68) based radiopharmaceutical cold kit developed by Juniper Biosciences for precision prostate cancer imaging. It is designed as a positron emission tomography (PET) imaging agent that binds directly to prostate-specific membrane antigen (PSMA) overexpressed on the surface of prostate cancer cells, rendering lesions visible on a whole-body scan. JBS-002 is utilized for staging men with high-risk prostate cancer before definitive treatment and localizing recurrence sites in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation.
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on JBS-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBS-002.